CorMedix Inc.
High uncertainty:The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
30.5% vs price
Base Case (Median)
143.1% vs price
Bull Case (75th pct.)
406.4% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $8.73 | 6.9% | High (40%) |
| PE Comparable | $47.40 | 480.2% | Medium (25%) |
| Graham Number | $16.42 | 101.0% | Medium (40%) |
| EV/EBITDA | $23.29 | 185.1% | Medium (20%) |
| EV/FCF | $69.89 | 755.4% | Medium (20%) |
| Earnings Power Value | $3.42 | -58.2% | Medium (50%) |
Based on 6 out of 8 methods, CRMD appears undervalued at the current price of $8.17. The base case fair value of $19.86 implies 143.1% upside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.